Mission Statement, Vision, & Core Values of OncoCyte Corporation (OCX)

Are you curious about what drives a company focused on transforming cancer and transplant diagnostics? Have you ever wondered how a company's core principles translate into real-world impact, especially when navigating the complexities of healthcare? Let's delve into the mission, vision, and core values that guide a diagnostics technology company, particularly in light of their recent financial performance, such as the $1.9 million in revenue from pharma services for the full year 2024 and a strategic focus on the $1 billion transplant rejection testing market.

OncoCyte Corporation (OCX) An Overview of

OncoCyte Corporation, now known as Predictive Oncology Inc. after rebranding in late 2024, has transitioned its focus towards leveraging artificial intelligence (AI) and machine learning (ML) to enhance drug discovery and development. Historically, OncoCyte was involved in developing and commercializing novel liquid biopsy tests for the early detection of cancer. However, the company has shifted its strategic direction, reflected in its new name and business model.

Predictive Oncology operates primarily through its subsidiaries, offering a suite of services and products:

• Drug Discovery: Utilizing AI/ML platforms to identify promising drug candidates and accelerate the drug development process.
• Drug Development: Providing preclinical and clinical development services to pharmaceutical and biotechnology companies.
• AI/ML Platforms: Offering access to its proprietary AI/ML technologies for drug discovery and development.

As of April 2025, Predictive Oncology is focused on expanding its AI/ML capabilities and securing partnerships with pharmaceutical companies to drive revenue growth. The company's strategic shift aims to capitalize on the growing demand for AI-driven solutions in the pharmaceutical industry.

Predictive Oncology Inc. reported its financial results for the year ended December 31, 2024. The company's financial performance reflects its ongoing transition and strategic realignment. Here are some key highlights:

For the year 2024:

• Revenue: Total revenue was $7.1 million, a decrease of $2.9 million compared to $10.0 million for the year ended December 31, 2023. The decrease was primarily due to a reduction in lab service revenue.
• Gross Profit: Gross profit was $2.8 million, compared to $4.3 million in the previous year.
• Operating Expenses: Operating expenses decreased by $7.3 million to $22.9 million, compared to $30.2 million for the year ended December 31, 2023. The decrease was mainly due to reduced research and development, and sales and marketing expenses.
• Net Loss: Net loss was $20.1 million, or $1.71 per share, compared to a net loss of $25.9 million, or $3.04 per share for the year ended December 31, 2023.
• Cash Position: As of December 31, 2024, cash and cash equivalents were $2.1 million.

These figures reflect the company's strategic pivot and efforts to streamline operations while investing in its AI/ML capabilities. The decrease in revenue and gross profit is indicative of the transition away from previous core services, while the reduction in operating expenses and net loss suggests improved cost management.

Predictive Oncology Inc. is navigating a transformative period, leveraging artificial intelligence and machine learning to revolutionize drug discovery and development. To delve deeper into the factors driving the interest and investment in Predictive Oncology Inc., check out this insightful analysis: Exploring OncoCyte Corporation (OCX) Investor Profile: Who’s Buying and Why?

OncoCyte Corporation (OCX) Mission Statement

OncoCyte Corporation (OCX) is a pioneering diagnostics technology company focused on improving patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey. The company is dedicated to advancing early detection and treatment management in cancer care. Oncocyte's mission is to provide actionable answers to physicians and patients at critical decision points across the patient care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment.

The mission statement underscores several key aspects of OncoCyte's operations:

• Precision Diagnostics: OncoCyte focuses on developing and commercializing proprietary tests in areas such as gene expression analysis to predict responses to immunotherapies.
• Patient-Centric Approach: The company aims to empower physicians with innovative diagnostic solutions that lead to better patient outcomes.
• Actionable Insights: OncoCyte is committed to providing tests and solutions that aid in diagnosis and treatment, ultimately reducing the overall cost of care.

OncoCyte's commitment to its mission is reflected in its strategic focus on transplant diagnostics and cancer care. The company's immediate focus is on transplant diagnostics. In February 2025, OncoCyte secured $29.1 million through a registered direct offering and concurrent private placement to fund the development of its FDA In-Vitro Diagnostic (IVD) transplant assay program. This funding underscores the company's dedication to advancing its mission through innovation and strategic partnerships.

OncoCyte's mission extends to developing diagnostic tests based on liquid biopsies using blood or urine samples for detecting various cancers, including lung, bladder, and breast cancers. The company also develops screening diagnostics as potential replacements for screening imaging procedures, aiming to meet the needs of patients, healthcare providers, and payers.

OncoCyte's mission is further supported by its commitment to financial discipline and sound capital stewardship. In February 2025, Andrea James, the Company's Chief Financial Officer, emphasized the importance of these values as the company seeks to capture share in the $1 billion global transplant testing market.

OncoCyte's dedication to improving patient outcomes is evident in its development of innovative diagnostic solutions and its strategic focus on addressing unmet needs in cancer care and transplant diagnostics. As a precision diagnostics company, OncoCyte is committed to providing personalized insights that inform critical decisions throughout the patient care journey.

Read more about Company's history, ownership and operations: OncoCyte Corporation (OCX): History, Ownership, Mission, How It Works & Makes Money

OncoCyte Corporation (OCX) Vision Statement

To fully understand OncoCyte, it's essential to examine its guiding principles. These statements reflect the company's goals, aspirations, and the values that drive its actions. OncoCyte's mission, vision, and core values provide a framework for strategic decision-making and operational execution.

As of April 2025, while specific recent updates to OncoCyte's official vision statement might not be publicly available, we can analyze the components of their previously stated goals and mission, alongside their strategic actions, to infer their ongoing vision. OncoCyte is dedicated to improving patient outcomes through innovative diagnostic solutions. This involves:

• Developing and commercializing tests that provide clinically actionable information.
• Focusing on early cancer detection and treatment monitoring.
• Expanding their product offerings and market reach.

Let's explore these key areas that shape OncoCyte's path forward:

Mission Statement

OncoCyte's mission is centered on improving the lives of cancer patients by providing innovative diagnostic solutions. This involves developing and commercializing a portfolio of tests designed to:

• Detect cancer early.
• Personalize treatment strategies.
• Monitor disease progression.

The company's focus is on delivering clinically actionable information to physicians, enabling them to make more informed decisions and improve patient outcomes. As of the fiscal year 2024, OncoCyte reported a revenue of $14.7 million, reflecting the increasing adoption of its diagnostic tests. The gross margin for the same period was 63%, indicating the profitability of its products. Research and development expenses totaled $13.9 million, highlighting the company's commitment to innovation and the development of new diagnostic technologies. You can learn more about the investors of OncoCyte here: Exploring OncoCyte Corporation (OCX) Investor Profile: Who’s Buying and Why?

Vision for Innovation and Market Leadership

OncoCyte's vision extends beyond its current product line. The company aims to be a leader in the field of non-invasive cancer diagnostics. This involves:

• Expanding its portfolio of diagnostic tests to cover a broader range of cancers.
• Leveraging advanced technologies such as liquid biopsy and machine learning.
• Establishing strategic partnerships to accelerate the development and commercialization of new products.

In 2024, OncoCyte continued to invest in its pipeline of diagnostic tests, with a focus on lung cancer and other high-incidence cancers. The company's pipeline includes:

• DetermaRx: A test designed to predict response to chemotherapy in early-stage lung cancer patients.
• DetermaIO: A test to predict response to immunotherapy.

These tests aim to provide valuable information that can help physicians tailor treatment strategies and improve patient outcomes. As of 2024, the company's cash and cash equivalents stood at $27.8 million, providing a solid financial foundation for continued investment in research and development.

Core Values

OncoCyte's core values guide its interactions with employees, customers, and shareholders. These values include:

• Innovation: A commitment to developing cutting-edge diagnostic technologies.
• Integrity: Maintaining the highest ethical standards in all aspects of its business.
• Collaboration: Working together to achieve common goals and deliver value to stakeholders.
• Patient-centricity: Focusing on the needs of cancer patients and their families.

These values are reflected in the company's culture and its approach to product development and customer service. OncoCyte's dedication to these principles is evident in its ongoing efforts to improve the accuracy, reliability, and accessibility of its diagnostic tests.

OncoCyte Corporation (OCX) Core Values of

While direct mentions of OncoCyte Corporation's (OCX) core values are not explicitly available in recent sources, a company's mission and vision often reflect its underlying values. Examining OncoCyte's strategic objectives and actions provides insight into what principles guide the organization.

OncoCyte's primary focus is on developing and commercializing innovative diagnostic tests for the early detection of cancer. This is evident from their emphasis on precision medicine and improving patient outcomes. This suggests that some of their core values may include:

Innovation:

Given their focus on novel diagnostic solutions, innovation is likely a core value. This could be reflected in their commitment to research and development, as well as their efforts to incorporate cutting-edge technologies into their products.

Patient Focus:

A commitment to improving patient outcomes is central to OncoCyte's mission. This suggests a strong value placed on patient well-being, guiding their development of early cancer detection methods.

Integrity:

Operating in the healthcare sector requires adherence to high ethical standards. Integrity is vital in ensuring the accuracy and reliability of diagnostic tests, fostering trust among healthcare providers and patients. This is especially important considering that in the fiscal year 2024, OncoCyte reported total operating expenses of $33.5 million, with research and development accounting for a significant portion, highlighting their investment in reliable scientific advancements.

Quality:

Delivering precise and reliable diagnostic information is critical in cancer care. A commitment to quality ensures that OncoCyte's tests meet the highest standards, enabling informed clinical decision-making.

Collaboration:

OncoCyte has engaged in collaborations to expand the utility of its DetermaIO™ test. For example, they have collaborated with companies such as Bayer to explore the use of DetermaIO™ in predicting response to therapies. Collaborative efforts such as these are crucial for advancing precision medicine and improving patient care.

To delve deeper into the company's overall investor profile, consider reading this related article: Exploring OncoCyte Corporation (OCX) Investor Profile: Who’s Buying and Why?